Balancing the efficacy and toxicity of chemotherapy in colorectal cancer

Therapeutic Advances in Medical Oncology

Volumn 3, Issue 1, 2011, Pages 43-52

  Braun, Michael S ^a   Seymour, Matthew T ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

colorectal cancer; combination chemotherapy; fluorouracil; irinotecan; oxaliplatin; performance status; staged chemotherapy; toxicity; treatment breaks

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; BLEEDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; COMORBIDITY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HYPERTENSION; INFECTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXICITY; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 79952826877     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834010388342     Document Type: Review

References (50)

1. Adams R.A. Meade A.M. Madi A. Fisher D. Kay E. Kenny S. et al (2009 a) Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 100 (2): 251–258.
2. Adams R. Wilson R. Seymour M.T. Meade A.M. Madi A. Cassidy J. et al (2009 b) Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: A randomised non-inferiority trial (MRC COIN). Eur J Cancer 7(Suppl): 10–11.
3. Amado R.G. Wolf M. Peeters M. van Cutsem E. Siena S. Freeman D.J. et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (10): 1626–1634.
4. Andre T. Boni C. Mounedji-Boudiaf L. Navarro M. Tabernero J. Hickish T. et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (23): 2343–2351.
5. Andre T. Boni C. Navarro M. Tabernero J. Hickish T. Topham C. et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27 (19): 3109–3116.
6. Best L. Simmonds P. Baughan C. Davis C. Fentiman I. George S. et al (2000) Palliative chemotherapy for advanced or metastatic colorectal cancer. Cochrane Database Syst Rev (1)): CD001545–CD001545.
7. Bokemeyer C. Bondarenko I. Makhson A. Hartmann J.T. Aparicio J. de Braud F. et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27 (5): 663–671.
8. Cassidy J. Twelves C. van Cutsem E. Hoff P. Bajetta E. Boyer M. et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13 (4): 566–575.
9. Chibaudel B. Maindrault-Goebel F. Lledo G. Mineur L. Andre T. Bennamoun M. et al (2009) Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX 2 Study. J Clin Oncol 27 (34): 5727–5733.
10. Cunningham D. Pyrhonen S. James R.D. Punt C.J. Hickish T.F. Heikkila R. et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 (9138): 1413–1418.
11. de Gramont A. Bosset J.F. Milan C. Rougier P. Bouche O. Etienne P.L. et al (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15 (2): 808–815.
12. de Gramont A. Figer A. Seymour M. Homerin M. Hmissi A. Cassidy J. et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (16): 2938–2947.
13. Douillard J.Y. Cunningham D. Roth A.D. Navarro M. James R.D. Karasek P. et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355 (9209): 1041–1047.
14. Douillard J. Siena S. Cassidy J. Tabernero J. Burkes R. Barugel M.E. et al (2009) Randomized phase 3 study of panitumumab with FOLFOX 4 compared to FOLFOX 4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): The PRIME trial. European Journal of Cancer 7S (3): 6–7, abstract LBA10.
15. Falcone A. Ricci S. Brunetti I. Pfanner E. Allegrini G. Barbara C. et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 25 (13): 1670–1676.
16. Folprecht G. Grothey A. Alberts S. Raab H.R. Kohne C.H. (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16: 1311–1319.
17. Goldberg R.M. Sargent D.J. Morton R.F. Fuchs C.S. Ramanathan R.K. Williamson S.K. et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (1): 23–30.
18. Goldberg R.M. Tabah-Fisch I. Bleiberg H. de Gramont A. Tournigand C. Andre T. et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil / leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24 (25): 4085–4091.
19. Grothey A. (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5(Suppl 1): S38–S46.
20. Hecht J.R. Mitchell E. Chidiac T. Scroggin C. Hagenstad C. Spigel D. et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27 (5): 672–680.
21. Jackson McLeary N.J. Meyerhardt J.A. Green E. Yothers G. de Gramont A. van Cutsem E. et al (2009) Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II / III colon cancer: Findings from the ACCENT Database. J Clin Oncol 27(15S): abstract 4010.
22. Karapetis C.S. Khambata-Ford S. Jonker D.J. O'Callaghan C.J. Tu D. Tebbutt N.C. et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (17): 1757–1765.
23. Kerr D.J. Gray R. McConkey C. Barnwell J. for the QUASAR Colorectal Cancer Study Group (2000) Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: Non-randomised comparison of weekly versus four-weekly schedules – less pain, same gain. Ann Oncol 11: 947–955.
24. Koopman M. Antonini N.F. Douma J. Wals J. Honkoop A.H. Erdkamp F.L. et al (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 370 (9582): 135–142.
25. Land S.R. Kopec J.A. Cecchini R.S. Ganz P.A. Wieand H.S. Colangelo L.H. et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25 (16): 2205–2211.
26. Ledermann J.A. Leonard P. Seymour M. (2001) Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345: 145–146.
27. Maughan T. Adams R.A. Smith C.G. Seymour M.T. Wilson R. Meade A.M. et al (2009) Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): A randomised superiority trial (MRC COIN). Eur J Cancer 7S (3): 4, abstract LBA6–4, abstract LBA6.
28. Maughan T.S. James R.D. Kerr D.J. Ledermann J.A. Seymour M.T. Topham C. et al (2003) Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicentre randomised trial. Lancet 361 (9356): 457–464.
29. Meta-analysis Group in Cancer. (1998 a) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 16: 301–308.
30. Meta-analysis Group in Cancer. (1998 b) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 16: 3537–3541.
31. Nordlinger B. Sorbye H. Glimelius B. Poston G.J. Schlag P.M. Rougier P. et al (2008) Perioperative chemotherapy with FOLFOX 4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 371 (9617): 1007–1016.
32. Nordlinger B. van Cutsem E. Gruenberger T. Glimelius B. Poston G. Rougier P. et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: Recommendations from an expert panel. Ann Oncol 20 (6): 985–992.
33. Quasar Collaborative Group, Gray R. Barnwell J. McConkey C. Hills R.K. Williams N.S. et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370 (9604): 2020–2029.
34. Saltz L.B. Clarke S. Diaz-Rubio E. Scheithauer W. Figer A. Wong R. et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26 (12): 2013–2019.
35. Saltz L.B. Cox J.V. Blanke C. Rosen L.S. Fehrenbacher L. Moore M.J. et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 (13): 905–914.
36. Saltz L.B. Niedzwiecki D. Hollis D. Goldberg R.M. Hantel A. Thomas J.P. et al (2007) Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 25 (23): 3456–3461.
37. Sargent D.J. Kohne C.H. Sanoff H.K. Bot B.M. Seymour M.T. de Gramont A. et al (2009) Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 27 (12): 1948–1955.
38. Sargent D.J. Niedzwiecki D. O'Connell M.J. Schilsky R.L. (2001) Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345: 144–145; author reply 146.
39. Seymour M.T. Maughan T.S. Ledermann J.A. Topham C. James R. Gwyther S.J. et al (2007 a) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 370 (9582): 143–152.
40. Seymour M.T. Maughan T.S. Wasan H.S. Brewster A.E. Shepherd S.F. O'Mahoney M.S. et al (2007 b) Capecitabine (Cap) and oxaliplatin (Ox) in elderly and / or frail patients with metastatic colorectal cancer: The FOCUS 2 trial. J Clin Oncol 25(18S): abstract 9030–abstract 9030.
41. Sorbye H. Pfeiffer P. Cavalli-Bjorkman N. Qvortrup C. Holsen M.H. Wentzel-Larsen T. et al (2009) Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 115 (20): 4679–4687.
42. Souglakos J. Androulakis N. Syrigos K. Polyzos A. Ziras N. Athanasiadis A. et al (2006) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): A multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94 (6): 798–805.
43. Tol J. Koopman M. Cats A. Rodenburg C.J. Creemers G.J. Schrama J.G. et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360 (6): 563–572.
44. Tournigand C. Andre T. Achille E. Lledo G. Flesh M. Mery-Mignard D. et al (2004) FOLFIRI Followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22 (2): 229–237.
45. Tournigand C. Cervantes A. Figer A. Lledo G. Flesch M. Buyse M. et al (2006) OPTIMOX1: A randomized study of FOLFOX 4 or FOLFOX 7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol 24 (3): 394–400.
46. Twelves C. Wong A. Nowacki M.P. Abt M. Burris 3rd H. Carrato A. et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 (26): 2696–2704.
47. van Cutsem E. Kohne C.H. Hitre E. Zaluski J. Chang Chien C.R. Makhson A. et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (14): 1408–1417.
48. van Cutsem E. Twelves C. Cassidy J. Allman D. Bajetta E. Boyer M. et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19 (21): 4097–4106.
49. Wolmark N. Wieand H.S. Kuebler J.P. Colangelo L. Smith R.E. (2005) A phase 3 trial comparing FULV to FU / LV + oxaliplatin in stage 2 or 3 carcinoma of the colon: Results of NSABP Protocol C-07. J Clin Oncol 23(Suppl): abstract 3500.
50. Yothers, G.A., O'Connell, M.J., Colangelo, L., Kuebler, J.P., Lopa, S., Findlay, M.P. et al. (2010) 5-FU and leucovorin (Lv) with or without oxaliplatin (Ox) for adjuvant treatment of stage II and III colon cancer: Long-term follow-up of NSABP C-07 with survival analysis. In: Proceedings of the ASCO Gastrointestinal Cancers Symposium, Orlando, Florida, abstract 401.